منابع مشابه
PCAI 52 - 59 - 16.3 - Random N.PDF
Introduction Have you played a video game lately? Purchased something on the web? Trained a Neural Network? Used a Genetic Algorithm for optimization? Run software from Microsoft? Applied textures to a photograph? Played the stock market? If the answer is “yes” to any of these questions, Random Number Generator (RNG) have affected your life. Can you trust your Random Number Generator? Can you t...
متن کامل52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
Section Editor: Sally A. Santen, MD, PhD Submission history: Submitted June 14, 2016; Revision received August 16, 2016; Accepted September 30, 2016 Electronically published November 21, 2016 Full text available through open access at http://escholarship.org/uc/uciem_westjem DOI: 10.5811/westjem.2016.9.31254 [West J Emerg Med. 2017;18(1):12-13.] Madigan Army Medical Center, Department of Emerge...
متن کاملPhytotaxa 7: 52–59 (2010) The new fern genus Calciphilopteris (Pteridaceae)
A new genus of Pteridaceae subfamily Cheilanthoideae is established for what has long been known as Doryopteris ludens. The newly erected genus is named Calciphilopteris in reference to its substrate specificity to limestone. Calciphilopteris can be found throughout Southeast Asia, from Indo-China to New Guinea and Australia. New combinations are established for the four known species (Calciphi...
متن کاملEffect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
BACKGROUND Antiviral treatment with nucleoside analogs has been used for chronic hepatitis B (CHB). Each kind of nucleoside analog has its own characteristics and suitability for patients. Telbivudine (LdT, brand name: Sebivo, Beijing Novartis Pharma Ltd) is the newest nucleoside analog, with strong and rapid viral suppression. However, its resistance rate is relatively high during long-term ap...
متن کاملDURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
OBJECTIVE In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study, the safety and efficacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonist exenatide once weekly (exenatide QW; 2 mg) was compared with exenatide BID in 295 patients with type 2 diabetes. We now report the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Diabetes
سال: 2012
ISSN: 0891-8929,1945-4953
DOI: 10.2337/diaclin.30.3.123